Clarke, N. W., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N., Procopio, G., … Saad, F. (2023). PROpel: Efficacy of abiraterone plus olaparib vs. abiraterone plus placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline. In EUROPEAN UROLOGY (Vol. 83).

Clarke, N. W., A. J. Armstrong, A. Thiery-Vuillemin, M. Oya, N. Shore, G. Procopio, J. D. Guedes, et al. “PROpel: Efficacy of abiraterone plus olaparib vs. abiraterone plus placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline.” In EUROPEAN UROLOGY, Vol. 83, 2023.

Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Procopio G, et al. PROpel: Efficacy of abiraterone plus olaparib vs. abiraterone plus placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline. In: EUROPEAN UROLOGY. 2023.

Clarke, N. W., et al. “PROpel: Efficacy of abiraterone plus olaparib vs. abiraterone plus placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline.” EUROPEAN UROLOGY, vol. 83, 2023.

Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, Schlurmann F, Joung JY, Sugimoto M, Sartor O, Poehlein C, Barker L, Degboe A, Saad F. PROpel: Efficacy of abiraterone plus olaparib vs. abiraterone plus placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline. EUROPEAN UROLOGY. 2023.